Company

From IMIB Spinoff to International Biomedical Benchmark

Bringing discoveries from the laboratory to the patient's bedside, redefining the management of inflammatory diseases.

About us

International biomedical reference

More information

Manifiesto

Viva in Vitro

More information

VIVA In Vitro Diagnostics was born in 2021 as the first spin off of IMIB (Instituto Murciano de Investigación Biosanitaria), with the mission of transforming research in immune diseases, bringing science to clinical application and patients.  

Meet VIVA-ELISA®:
Innovation at the Service of Personalised Medicine

Patented technology that anticipates clinical risk when every minute counts.

Find out more in Products and Services

Acknowledgements

Recognised excellence in biomedical innovation

European Innovation Council (EIC)

The European Innovation Council (EIC) selects Viva in Vitro Diagnostics as one of the 40 most disruptive European companies, awarding us €2.5 million in non-dilutive funding from the EIC Transition programme. 

Business Acceleration Services (BAS)

The EU has incorporated Viva in Vitro into its pioneering Business Acceleration Services (BAS) , in which it facilitates the maturing of disruptive new technologies, building solid business cases and connecting with institutions, corporations and private companies. 

Murcia Region Entrepreneur of the Year Award 2022

Organised by the
Consejería de Economía, Hacienda y Empresa, through the Instituto de Fomento (Info).

CEI Mare Nostrum 2022 Award

It recognises Viva In Vitro’s commitment to improving healthcare and reducing hospital mortality worldwide..

Impact Business 2023 Initiative Award

From the Ship2B Foundation. Successful completion of its Health&Care Acceleration programme.

Innovative SME Seal by ENISA

By the Ministry of Tourism and Trade, in 2023

EIBT Seal

Innovative Technology-Based Company Seal by ANCES (National Association of CEEIs).

Company of the Year Award 2023

Awarded by Banco Sabadell, in recognition of our excellence in biomedical innovation.

Isaac Foundation Research Award 2024

Edition 2024, for our disruptive contribution to the detection and stratification of sepsis. /p>

Roadmap: Key Milestones and Next Steps
2021

Foundation of VIVA In Vitro Diagnostics.

2022

First round of funding: €275K. and ENISA financing for 195K €

2023
  • Second round of funding (€880K + Neotec €250K + INFO EPTE €44K).
  • Establishment of headquarters and consolidation of the key team.
2024
  • Development of the regulatory roadmap.
  • Implementation of trade secret protocols.
  • Funding round €1,340K.
  • Clinical validation and TRL4 validation agreements.
  • Quality ISO 13458.
2025-2026-2027
  • Development of EIC Transition programme. 2.5 M € (INFO EPTE-Investors 170K €): ELISA RUO.
  • Elisa optimised for clinical use, clinical validation.
  • Regulatory.
  • Quality ISO 13485.
  • Manufacturing plan, expansion into new therapeutic areas and optimisation of clinical data.
  • Dissemination programme, marketing roadmap.
2028-2029
  • Obtaining FDA/EC certifications and commercial launch of the automated ELISA device.
See full Roadmap.
In Pre-Clinical Validation

The agreement signed with the Fundación para la Formación e Investigación Sanitarias de la Región de Murcia, dependent on the Servicio Murciano de Salud, and the Fundación para la Investigación de Málaga en Biomedicina y Salud and Fundación para la Gestión de la investigación Biomédica de Cádiz, dependent on the Servicio Andaluz de Salud, will allow us to pre-validate clinical markers that will provide key information for early and accurate prognosis of sepsis, patient stratification and progress towards personalised medicine to improve medical intervention.

More information
News
See all news

Join the cutting edge of biomedical research

Subscribe to VIVA Insights: The leading newsletter on inflammasomes and sepsis 

Receive exclusive analysis, scientific breakthroughs and collaboration opportunities from our network of international partners and benchmarks.

funded-europe
  • Murcia Science Park, Building T, 1st Floor (Module T1/3). Ctra. Madrid km. 388 30100 Murcia
  • +34 601 995 952
  • info@vivaivd.com
Linkedin
Esta web está diseñada y programada por Pantumaka Comunicación. Agencia de publicidad y marketing digital en Murcia.
About us: International biomedical reference

We are recognized as an international biomedical benchmarks in the biomedical sector, chosen by the European Innovation Council of the European Commission as one of the most disruptive companies in the field. 

Our company is built on a solid foundation of cutting-edge research and robust financial backing, reinforced by national and international programmes and awards that recognize our potential to lead and grow within the biomedical sector.

With a multidisciplinary and global team combining experts in immunology, biotechnology, biomedical engineering and a management team with international experience in biomedical project management, advising public institutions and managing high-growth companies.

We are a strong and effective partner at the cutting edge of biomedical research.
Discover our team and collaborators
OUR COMMITMENT TO LIFE
Mission

Anticipating sepsis when every hour counts. We develop reliable, easy-to-use tools that allow clinicians to stratify patients by immune status, severity and prognosis hours earlier than current methods, facilitating personalisation of their treatment and improving the use of precious ICU and emergency resources.   

Vision

We aim to lead the new era of precision immunology-based diagnostics and also to facilitate the development of new therapies, first in sepsis, then in other conditions, such as cardiovascular, renal, neurodegenerative or cancers.  

In this way, we realise our commitment to patients, society and shareholders by improving care, reducing hospital costs and waste, ultimately helping to reduce suffering and save lives. 

Our values
    • EXCELLENCE: We use cutting-edge science and the most demanding development, validation and management tools to detect problems before they become apparent through other techniques.

 

    • RIGOUR AND ACCURACY: We provide specific and actionable information for doctors, rigorously validated through scientific, clinical and regulatory standards.

    • INTEGRATION AND IMPACT: We design patient-friendly solutions for healthcare markets that integrate into existing hospital workflows, and easy for clinicians to use in their day-to-day environment.

  • 2021
    VIVA In Vitro Diagnostics Fundation
  • 2022
    First round of funding: €275K. ENISA financing for 195K €.
  • 2023
    -Second round of funding (€880K + Neotec €250K + INFO EPTE €44K).
    -Establishment of headquarters and consolidation of the key team.
  • 2024
    – Development of the regulatory roadmap.
    – Implementation of trade secret protocols.
    – Funding round €1,340K.
    – Clinical validation and TRL4 validation agreements.
    – Quality ISO 13458.
  • 2025-2026-2027
    – Development of EIC Transition programme. 2.5 M € (INFO EPTE-Investors 170K €): ELISA RUO.
    – Elisa optimised for clinical use, clinical validation.
    – Regulatory.
    – Quality ISO 13485.
    – Manufacturing plan, expansion into new therapeutic areas and optimisation of clinical data.
    – Dissemination programme, marketing roadmap.
  • 2028-2029
    – Obtaining FDA/EC certifications
    – Commercial launch of the automated ELISA device.